Clinical Report: Thoracic Spinal Metastasis Observed Without Clear Intrahepatic Recurrence

Overview

This case study highlights the detection of thoracic spinal metastasis in a patient with hepatocellular carcinoma (HCC) who underwent conversion therapy and hepatectomy, despite no clear intrahepatic recurrence.

Background

Hepatocellular carcinoma (HCC) management has evolved with the integration of various therapies, including conversion therapy and hepatectomy. While effective in controlling intrahepatic disease, the risk of extrahepatic progression, particularly to the spine, poses significant clinical challenges.

Data Highlights

No numerical data or trial data provided in the article.

Key Findings

• A 61-year-old man with hepatitis B-related HCC experienced thoracic spinal metastasis post-hepatectomy.
• Despite effective intrahepatic control, rising alpha-fetoprotein and des-gamma-carboxy prothrombin levels indicated potential extrahepatic disease.
• Initial imaging did not reveal spinal involvement, leading to delayed diagnosis of multilevel thoracic metastases.
• Prompt intervention was required after neurological deterioration due to spinal cord compression.

Clinical Implications

Healthcare professionals should consider additional imaging modalities when monitoring HCC patients, especially when tumor markers rise without clear intrahepatic recurrence. Multidisciplinary evaluations are essential for timely intervention in cases of suspected extrahepatic progression.

Conclusion

This case illustrates the detection of extrahepatic disease in HCC patients, particularly when tumor markers indicate potential progression despite negative liver imaging.

Related Resources & Content

1. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma - PMC, 2023 -- AASLD Guidance
2. Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial - PubMed, 2026 -- SILENSES Trial
3. Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study - PMC, 2023 -- Extrahepatic Recurrence Study
4. Frontiers in Immunology — Efficacy of combined modality conversion therapy for HCC with portal vein tumor thrombus: a retrospective cohort study
5. Frontiers in Immunology — Case Report: Tumor regression and neurological recovery in paraplegia from POLD1-mutated hepatocellular carcinoma treated with targeted immunotherapy and electroacupuncture
6. Frontiers in Oncology — Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma
7. Outcomes of Treatment and Predictive Factors in Colorectal Cancer Patients with Concurrent Lung Metastases During the Era of Conversion Therapy
8. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma - PMC
9. Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial - PubMed
10. Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study - PMC